BioNTech (BNTX) Q4 FY25 earnings call

BioNTech reported strong Q4 and full-year 2025 financial results, exceeding revenue guidance and maintaining a robust cash position, despite declining COVID-19 vaccine revenues. The company is strategically advancing its oncology pipeline, with multiple late-stage readouts expected in 2026, and is preparing for its first oncology launches. Founders Ugur Sahin and Ozlem Tureci announced their transition to lead a new independent company focused on next-generation mRNA innovations by the end of 2026, with BioNTech retaining a minority stake and continuing its focus on its existing late-stage pip